The financials
Boston Scientific by the numbers
Boston Scientific (BSX) reported revenue of $5.44B in Q2 2026 (quarter ended June 30, 2026), up 7.5% from the same quarter a year earlier. That came with a gross margin of 71% and net income of $905M (17% of revenue). For the full year FY2025, revenue was $20.1B (+20% year on year) and net income $2.89B. Its largest product in 2026-Q2 was Electrophysiology EP at $606M, 18% of the disclosed total, just ahead of Interventional Cardiology Therapies at 17%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $5.44B | $5.06B | +7.5% |
| Gross profit | $3.85B | $3.42B | +12% |
| Operating income | $1.18B | $819M | +44% |
| Net income | $905M | $795M | +14% |
| Diluted EPS | $0.61 | $0.53 | +15% |
| Product | Revenue | Share |
|---|---|---|
| Electrophysiology EP | $606M | 18% |
| Interventional Cardiology Therapies | $586M | 17% |
| Global Urologyand Pelvic Health Reporting Unit | $503M | 15% |
| Global Endoscopy Endo Reporting Unit | $491M | 14% |
| Watchman | $459M | 13% |
| Cardiac Rhythm Management | $349M | 10% |
| Global Neuromodulation Nm Reporting Unit | $257M | 7.5% |
| Interventional Oncology And Embolization | $175M | 5.1% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $3.43B (+4.4%)
Interventional Cardiology Therapies grew +17% year on yearCardiac Rhythm Management -1.7% year on year
Segment Latestquarter on quarteryear on year
- Electrophysiology EP$606.0M$606.0MQoQ +0.50%year on year +3.2%+0.50%+3.2%
- Interventional Cardiology Therapies$586.0M$586.0MQoQ +6.2%year on year +17%+6.2%+17%
- Global Urology and Pelvic Health Reporting Unit$503.0M$503.0MQoQ +8.2%year on year +0.80%+8.2%+0.80%
- Global Endoscopy Endo Reporting Unit$491.0M$491.0MQoQ +10%year on year +7.7%+10%+7.7%
- Watchman$459.0M$459.0MQoQ -0.65%year on year +2.9%-0.65%+2.9%
- Cardiac Rhythm Management$349.0M$349.0MQoQ 0.00%year on year -1.7%0.00%-1.7%
- Global Neuromodulation Nm Reporting Unit$257.0M$257.0MQoQ +8.9%year on year +13%+8.9%+13%
- Interventional Oncology And Embolization$175.0M$175.0MQoQ +2.9%year on year +13%+2.9%+13%
- Global Cardiology Reporting Unit--QoQ -year on year ---
- Global Peripheral Interventions Pi Reporting Unit--QoQ -year on year ---
Medical Devices
Ranks #24 of 35 by Smart Score